On 1 July, the official website of the National Medical Products Administration (NMPA) showed that HUTCHMED’s savolitinib had been approved for a new indication: the treatment of adult patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with MET gene amplification who have failed at least two prior systemic chemotherapy regimens.
Savolitinib is an oral, highly selective c‑Met inhibitor developed by HUTCHMED. It blocks aberrant activation of the MET receptor tyrosine kinase signalling pathway caused by mutations (e.g., exon 14 skipping mutations or other point mutations), gene amplification, or protein overexpression.
In December 2011, AstraZeneca entered into a collaboration agreement with HUTCHMED, under which AstraZeneca leads the development of savolitinib in China, while AstraZeneca oversees overseas development. In addition, HUTCHMED is responsible for the marketing authorisation, manufacturing, and supply of savolitinib in China, and AstraZeneca is responsible for its commercialisation both in China and globally.
In June 2021, savolitinib received conditional approval in China for the treatment of patients with MET exon 14 skipping mutation NSCLC who have progressed after systemic therapy or are unable to receive chemotherapy. In January 2025, savolitinib tablets received approval for a second indication: the treatment of treatment‑naïve patients with MET exon 14 skipping mutation NSCLC. In June 2025, it received approval for a third indication: in combination with osimertinib for the treatment of EGFR mutation‑positive locally advanced or metastatic NSCLC patients with MET amplification who have progressed on first‑line EGFR‑TKI therapy.